Back to Browse Journals » Vascular Health and Risk Management » Volume 3 » Issue 4

Arterial Stiffness and Pharmacological Interventions – The TRanscend Arterial stiffNess Substudy (TRANS study)

Authors Jirar Topouchian, Ramzi El Feghali, Bruno Pannier, Shuyu Wang, Feng Zhao, Karel Smetana, Koon Teo, Roland Asmar

Published Date October 2007 Volume 2007:3(4) Pages 381—388

DOI http://dx.doi.org/

Published 4 October 2007

Jirar Topouchian1, Ramzi El Feghali1, Bruno Pannier1, Shuyu Wang2, Feng Zhao3, Karel Smetana4, Koon Teo3, Roland Asmar1

1The CardioVascular Institute, Paris, France; 2Beijing Clinical Trial and Research Center, Beijing, China; 3Population Health Research Institute, Hamilton, Canada; 4Vojenska nemocnice Plzen, Pizen, Czech Republic

Abstract: The degree of arterial stiffness is correlated with the risk of cardiovascular diseases and it is a powerful predictor for morbidity and mortality. Studies have shown that arterial stiffness reduction is associated with an improvement in survival. Reduction of arterial stiffness by pharmacological drugs varies according to the drugs and doses used and duration of treatment. This effect on the arteries differs among the various classes of drugs and among individual drugs in the same class. Quantification of the stiffness and other properties of the arterial wall can be used to monitor the responses to therapy in individuals with hypertension and other cardiovascular diseases. These measures can then be used as surrogate markers for the risk of clinical events. Inhibition of the renin-angiotensin system (RAS) is associated with an important decrease in cardiovascular risk. Findings from clinical trials support the hypothesis that the protective effects of RAS inhibition are partly independent from blood pressure reduction and related to several mechanisms including vascular protective effects. The aim of the TRanscend Arterial stiffNess Substudy (TRANS) is to assess the effect of an angiotensin II receptor blocker (ARB), telmisartan, on the arterial stiffness in a subgroup of patients from the Telmisartan Randomized Assessment Study in aCE iNtolerant subjects with cardiovascular Disease (TRANSCEND) trial. The TRANSCEND trial is an international, multicenter, randomized double blind placebo controlled trial of telmisartan that enrolled patients at high risk for cardiovascular events. Some clinical baseline data of the TRANS substudy are reported. When completed, the results of the TRANS substudy will show whether the beneficial effects of treatment with telmisartan on cardiovascular outcome may be related to an improvement in arterial stiffness.

Keywords: arterial stiffness, cardiovascular prevention, ARBs, telmisartan, pulse wave velocity, antihypertensive

Download Article [PDF] 

Readers of this article also read:

Applications of gold nanoparticles in cancer nanotechnology

Weibo Cai, Ting Gao, Hao Hong, Jiangtao Sun

Nanotechnology, Science and Applications 2008, 1:17-32

Published Date: 19 September 2008

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009

HbA1c is associated with severity of obstructive sleep apnea hypopnea syndrome in nondiabetic men

Nikolaos Papanas, Paschalis Steiropoulos, Evangelia Nena, et al

Vascular Health and Risk Management 2009, 5:751-756

Published Date: 8 September 2009

Prolonged rupture of membranes in term infants: should all babies be screened?

Christopher Flannigan, Martina Hogan

Clinical Audit 2010, 2:1-6

Published Date: 9 February 2010

Recent achievements in the management of Raynaud’s phenomenon

Magnus Baumhäkel, Michael Böhm

Vascular Health and Risk Management 2010, 6:207-214

Published Date: 30 March 2010

Neurotransmitter testing of the urine: a comprehensive analysis

Marty Hinz, Alvin Stein, George Trachte, et al

Research and Reports in Urology 2010, 2:177-183

Published Date: 7 October 2010

Facial transplantation: a review of ethics, progress, and future targets

Edwards JA, Mathes DW

Transplant Research and Risk Management 2011, 3:113-125

Published Date: 5 September 2011

Aggressive behavior, cognitive impairment, and depressive symptoms in elderly subjects

Margari F, Sicolo M, Spinelli L, Mastroianni F, Pastore A, Craig F, Petruzzelli MG

Neuropsychiatric Disease and Treatment 2012, 8:347-353

Published Date: 1 August 2012